Abstract
Accumulating studies have provided concrete evidence that p90 ribosomal S6 kinase 2 (RSK2) is a key signaling molecule involved in cell proliferation, transformation, and cancer development. RSK2 is known to be an etiological gene of Coffin-Lowry Syndrome (CLS). Recently, signaling analysis and molecular biological approaches have provided concrete evidence that RSK2 plays an essential role in human cancers. Here, we will extensively discuss signaling pathways regulating RSK2 activity, the role of RSK2 in human cancer development, inhibitors suppressing RSK2 activity, and why RSK2 is an important target to develop drugs for human cancers.
Keywords: Ras signaling pathway, ERK/RSK2, cell proliferation, carcinogenesis, cancer, emerging target.
Current Pharmaceutical Design
Title:Molecular Targeting of ERKs/RSK2 Signaling in Cancers
Volume: 23 Issue: 29
Author(s): Yong-Yeon Cho*
Affiliation:
- BK21 PLUS Team for Creative Leader Program for Pharmacomics-based Future Pharmacy, Integrated Research Institute of Pharmaceutical Sciences, College of Pharmacy, The Catholic University of Korea, 43, Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 420-743,Korea
Keywords: Ras signaling pathway, ERK/RSK2, cell proliferation, carcinogenesis, cancer, emerging target.
Abstract: Accumulating studies have provided concrete evidence that p90 ribosomal S6 kinase 2 (RSK2) is a key signaling molecule involved in cell proliferation, transformation, and cancer development. RSK2 is known to be an etiological gene of Coffin-Lowry Syndrome (CLS). Recently, signaling analysis and molecular biological approaches have provided concrete evidence that RSK2 plays an essential role in human cancers. Here, we will extensively discuss signaling pathways regulating RSK2 activity, the role of RSK2 in human cancer development, inhibitors suppressing RSK2 activity, and why RSK2 is an important target to develop drugs for human cancers.
Export Options
About this article
Cite this article as:
Cho Yong-Yeon *, Molecular Targeting of ERKs/RSK2 Signaling in Cancers, Current Pharmaceutical Design 2017; 23 (29) . https://dx.doi.org/10.2174/1381612823666170714142338
DOI https://dx.doi.org/10.2174/1381612823666170714142338 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Trichinella spiralis and Tumors: Cause, Coincidence or Treatment?
Anti-Cancer Agents in Medicinal Chemistry Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine Graphene Oxide: A Carrier for Pharmaceuticals and a Scaffold for Cell Interactions
Current Topics in Medicinal Chemistry Vacuolar H+-ATPase Signaling Pathway in Cancer
Current Protein & Peptide Science Apoptosis and Apoptosis-Based Therapy in Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Investigating ABCB1-Mediated Drug-Drug Interactions: Considerations for In vitro and In vivo Assay Design
Current Drug Metabolism Nasal Polyposis: An Overview of Differential Diagnosis and Treatment
Recent Patents on Inflammation & Allergy Drug Discovery Increased Expression of Matrix Metalloproteinases Mediates Thromboxane A2-Induced Invasion in Lung Cancer Cells
Current Cancer Drug Targets Players in ADP-ribosylation: Readers and Erasers
Current Protein & Peptide Science Molecular Mechanisms of Tumor Invasion and Metastasis: An Integrated View
Current Molecular Medicine Mast Cells as Target in Cancer Therapy
Current Pharmaceutical Design Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Molecular Based Drug Targets for Idiopathic Pulmonary Fibrosis
Current Respiratory Medicine Reviews Molecular Predictors of Efficacy to Anti-EGFR Agents in Colorectal Cancer Patients
Current Cancer Drug Targets Genetics and Epigenetics of Lung Cancer: Mechanisms and Future Perspectives
Current Cancer Therapy Reviews Phytoestrogens and Prostate Cancer
Current Drug Targets Proteasome Inhibitors Therapeutic Strategies for Cancer
Recent Patents on Anti-Cancer Drug Discovery Editorial [ Hot Topic: Targeting Tumor Angiogenesis: An Update (Guest Editor: Girolamo Ranieri)]
Current Medicinal Chemistry Medical Expert Systems
Current Bioinformatics miRNAs as Modulators of Cholesterol in Breast Cancer Stem Cells: An Approach to Overcome Drug Resistance in Cancer
Current Drug Targets